BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019-1026. [PMID: 31915235 DOI: 10.1136/gutjnl-2019-319954] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Ansari M, Hossein Mahvi A, Hossein Salmani M, Sharifian M, Fallahzadeh H, Hassan Ehrampoush M. Dielectric barrier discharge plasma combined with nano catalyst for aqueous amoxicillin removal: Performance modeling, kinetics and optimization study, energy yield, degradation pathway, and toxicity. Separation and Purification Technology 2020;251:117270. [DOI: 10.1016/j.seppur.2020.117270] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
2 Gudra D, Pupola D, Skenders G, Leja M, Radovica-Spalvina I, Gorskis H, Vangravs R, Fridmanis D. Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event. Helicobacter 2020;25:e12748. [PMID: 32776403 DOI: 10.1111/hel.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gunaratne AW, Hamblin H, Clancy A, Magat AJMC, Dawson MVM, Tu J, Borody TJ. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study. Helicobacter 2021;:e12830. [PMID: 34247436 DOI: 10.1111/hel.12830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Graham DY, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol 2021;36:1159-63. [PMID: 32918832 DOI: 10.1111/jgh.15252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fujimoto S, Tsuruoka N, Esaki M, Takamori A, Sakata Y, Shimoda R, Akutagawa T, Node K, Anzai K, Sugisaki N, Iwakiri R, Takagi K, Yamanouchi K, Fujimoto K. Decline incidence in upper gastrointestinal bleeding in several recent years: data of the Japan claims database of 13 million accumulated patients. J Clin Biochem Nutr 2021;68:95-100. [PMID: 33536718 DOI: 10.3164/jcbn.20-153] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Reference Citation Analysis]
8 O'connor A, Furuta T, Gisbert JP, O'morain C. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25. [DOI: 10.1111/hel.12743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hu Y, Xu X, Ouyang Y, He C, Li N, Xie C, Peng C, Zhu Z, Xie Y, Shu X, Lu N, Zhu Y. Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: A prospective, randomized clinical pilot study. Helicobacter. [DOI: 10.1111/hel.12896] [Reference Citation Analysis]
10 Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut 2021:gutjnl-2021-326170. [PMID: 34750206 DOI: 10.1136/gutjnl-2021-326170] [Reference Citation Analysis]
11 Horii T, Suzuki S, Takano C, Shibuya H, Ichijima R, Kusano C, Ikehara H, Gotoda T. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol 2021. [PMID: 34107551 DOI: 10.1111/jgh.15572] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth. Yonsei Med J 2021;62:708-16. [PMID: 34296548 DOI: 10.3349/ymj.2021.62.8.708] [Reference Citation Analysis]
13 Seyedmajidi MR, Hosseini SA, Vafaeimanesh J. Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in Eradicating Helicobacter Pylori. Middle East J Dig Dis 2021;13:131-8. [PMID: 34712451 DOI: 10.34172/mejdd.2021.216] [Reference Citation Analysis]
14 Nabavi-rad A, Azizi M, Jamshidizadeh S, Sadeghi A, Aghdaei HA, Yadegar A, Zali MR, Niedźwiedzka-rystwej P. The Effects of Vitamins and Micronutrients on Helicobacter pylori Pathogenicity, Survival, and Eradication: A Crosstalk between Micronutrients and Immune System. Journal of Immunology Research 2022;2022:1-22. [DOI: 10.1155/2022/4713684] [Reference Citation Analysis]
15 Zhao Y, Yang Y, Aruna, Xiao J, Song J, Huang T, Li S, Kou J, Huang L, Ji D, Xiong S, Peng W, Xu S, Cheng B. Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Front Med (Lausanne) 2021;8:776955. [PMID: 34869495 DOI: 10.3389/fmed.2021.776955] [Reference Citation Analysis]
16 Feng XY, Zhang Y, Deng B. Progress in research of high-dose dual therapy as an eradication protocol for Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 847-851 [DOI: 10.11569/wcjd.v28.i17.847] [Reference Citation Analysis]
17 Zhong Y, Tang L, Deng Q, Jing L, Zhang J, Zhang Y, Yu F, Ou Y, Guo S, Huang B, Cao H, Huang P, Xu Y. Unraveling the Novel Effect of Patchouli Alcohol Against the Antibiotic Resistance of Helicobacter pylori. Front Microbiol 2021;12:674560. [PMID: 34149664 DOI: 10.3389/fmicb.2021.674560] [Reference Citation Analysis]
18 Hirata Y, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin‐based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single‐arm study. Helicobacter 2020;25. [DOI: 10.1111/hel.12719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Furuta T, Yamade M, Kagami T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K. Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of H. pylori. Gut 2020;69:2056.2-2056. [DOI: 10.1136/gutjnl-2020-320705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol 2021;14:17562848211064080. [PMID: 34987609 DOI: 10.1177/17562848211064080] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Howden CW, Graham DY. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol 2021;116:1-3. [PMID: 33378314 DOI: 10.14309/ajg.0000000000001031] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Chen LW, Chang LC, Hua CC, Liu CJ, Chou TS, Lin CL, Chien RN. The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. J Clin Med 2021;10:4352. [PMID: 34640370 DOI: 10.3390/jcm10194352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, Kawai Y, Fujimiya T, Takeuchi H, Unezaki S, Kawai T. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol 2021;12:759249. [PMID: 34721043 DOI: 10.3389/fphar.2021.759249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Curr Treat Options Gastroenterol 2020;:1-12. [PMID: 32837180 DOI: 10.1007/s11938-020-00300-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
29 Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
30 Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol 2020;55:1054-61. [PMID: 32930864 DOI: 10.1007/s00535-020-01723-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Shen C, Li C, Lv M, Dai X, Gao C, Li L, Zhang Q, Pan W, Liu C, Han S, Zhang Y, Ding S, Deng H, Yao Y, Xu J, Wei M, Shi H, Yuan P, Yang X, Jian Y, Shan J, Liu Y, Chen Z, Deng X, Liu F, Deng L, Zhong X, Li H, He S, Chen L, Liu G, Xu H, Zhong Y, Shi H, Ren J; Multi-Center Clinical Research Collaboration Group of Sichuan Provincial H. pylori Scientific Group, Sichuan Provincial Medical Association. The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas. Ann Med 2022;54:426-35. [PMID: 35098820 DOI: 10.1080/07853890.2022.2031269] [Reference Citation Analysis]
32 Shimada F, Endo H, Takamori A, Matsunaga T, Fujimoto S, Shirai S, Kakiuchi T, Akutagawa T, Sakata Y, Node K, Yamanouchi K, Nakamura S, Fujimoto K, Esaki M. Lifestyle- and comorbidity-related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan. JGH Open 2021;5:1284-8. [PMID: 34816014 DOI: 10.1002/jgh3.12666] [Reference Citation Analysis]
33 Argueta EA, Moss SF. Management of Helicobacter pylori. Curr Opin Gastroenterol 2020;36:518-24. [PMID: 32868505 DOI: 10.1097/MOG.0000000000000678] [Reference Citation Analysis]
34 Suzuki S, Gotoda T, Takano C, Horii T, Sugita T, Ogura K, Ichijima R, Kusano C, Ikehara H. Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes. Helicobacter 2021;26:e12851. [PMID: 34486195 DOI: 10.1111/hel.12851] [Reference Citation Analysis]
35 Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol 2021;14:1756284821989177. [PMID: 34262609 DOI: 10.1177/1756284821989177] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021;26:e12788. [PMID: 33580612 DOI: 10.1111/hel.12788] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Yang JC, Kao JY. Treatment considerations in Helicobacter pylori management. Aliment Pharmacol Ther 2022;55 Suppl 1:S22-8. [PMID: 34989432 DOI: 10.1111/apt.16652] [Reference Citation Analysis]
38 Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J Gastroenterol 2020;55:969-76. [DOI: 10.1007/s00535-020-01709-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM;  Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093-2112. [PMID: 33004546 DOI: 10.1136/gutjnl-2020-322368] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
40 Suzuki H, Mori H. Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next? United European Gastroenterol J 2021;9:7-8. [PMID: 33210981 DOI: 10.1177/2050640620975357] [Reference Citation Analysis]